Cancer Pain Management and Bone Metastases: An Update for the Clinician

被引:34
作者
Schneider, Guido [1 ,2 ,3 ]
Voltz, Raymond [1 ,2 ,3 ]
Gaertner, Jan [1 ,2 ,3 ]
机构
[1] Univ Hosp Cologne, Dept Palliat Care, D-50924 Cologne, Germany
[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany
[3] Cologne Clin Trials Ctr, Cologne, Germany
关键词
Breast cancer; Palliative care; Palliative medicine; Bone metastases; Cancer pain; Opioids; Guidelines; QUALITY-OF-LIFE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EVIDENCE-BASED-RECOMMENDATIONS; NEUROPATHIC PAIN; OPIOID ROTATION; ORAL METHADONE; DOUBLE-BLIND; CARE; RELEASE; MODERATE;
D O I
10.1159/000338579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer patients with bone metastases often suffer from cancer pain. In general, cancer pain treatment is far from being optimal for many patients. To date, morphine remains the gold standard as first-line therapy, but other pure mu agonists such as hydromorphone, fentanyl, or oxycodone can be considered. Transdermal opioids are an important option if the oral route is impossible. Due to its complex pharmacology, methadone should be restricted to patients with difficult pain syndromes. The availability of a fixed combination of oxycodone and naloxone is a promising development for the reduction of opioid induced constipation. Especially bone metastases often result in breakthrough pain episodes. Thus, the provision of an on-demand opioid (e.g., immediate-release morphine or rapid-onset fentanyl) in addition to the baseline (regular) opioid therapy (e.g., sustained-release morphine tablets) is mandatory. Recently, rapid onset fentanyls (buccal or nasal) have been strongly recommended for breakthrough cancer pain due to their fast onset and their shorter duration of action. If available, metamizole is an alternative non-steroid-anti-inflammatory-drug. The indication for bisphosphonates should always be checked early in the disease. In advanced cancer stages, glucocorticoids are an important treatment option. If bone metastases lead to neuropathic pain, coanalgetics (e.g., pregabalin) should be initiated. In localized bone pain, radiotherapy is the gold standard for pain reduction in addition to pharmacologic pain management. In diffuse bone pain radionuclids (such as samarium) can be beneficial. Invasive measures (e.g., neuroaxial blockage) are rarely necessary but are an important option if patients with cancer pain syndromes are refractory to pharmacologic management and radiotherapy as described above. Clinical guidelines agree that cancer pain management in incurable cancer is best provided as part of a multiprofessional palliative care approach and all other domains of suffering (psychosocial, spiritual, and existential) need to be carefully addressed ('total pain').
引用
收藏
页码:113 / 120
页数:8
相关论文
共 61 条
[1]   A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain [J].
Ahmedzai, Sam H. ;
Nauck, Friedemann ;
Bar-Sela, Gil ;
Bosse, Bjoern ;
Leyendecker, Petra ;
Hopp, Michael .
PALLIATIVE MEDICINE, 2012, 26 (01) :50-60
[2]   Effective Delivery of Pharmaceutical Palliative Care: Challenges in the Community Pharmacy Setting [J].
Akram, Gazala ;
Bennie, Marion ;
McKellar, Susan ;
Michels, Susanna ;
Hudson, Stephen ;
Trundle, Janet .
JOURNAL OF PALLIATIVE MEDICINE, 2012, 15 (03) :317-321
[3]  
Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302
[4]   Efficacy of complementary and alternative medicine therapies in relieving cancer pain: A systematic review [J].
Bardia, Aditya ;
Barton, Debra L. ;
Prokop, Larry J. ;
Bauer, Brent A. ;
Moynihan, Timothy J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5457-5464
[5]   Pathophysiology and Animal Models of Cancer-Related Painful Peripheral Neuropathy [J].
Bennett, Gary J. .
ONCOLOGIST, 2010, 15 :9-12
[6]   Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review [J].
Bennett, Michael I. ;
Rayment, Clare ;
Hjermstad, Marianne ;
Aass, Nina ;
Caraceni, Augusto ;
Kaasa, Stein .
PAIN, 2012, 153 (02) :359-365
[7]   Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study [J].
Bruera, E ;
Palmer, JL ;
Bosnjak, S ;
Rico, MA ;
Moyano, J ;
Sweeney, C ;
Strasser, F ;
Willey, J ;
Bertolino, M ;
Mathias, C ;
Spruyt, O ;
Fisch, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :185-192
[8]   Methadone for treatment of cancer pain [J].
Bryson J. ;
Tamber A. ;
Seccareccia D. ;
Zimmermann C. .
Current Oncology Reports, 2006, 8 (4) :282-288
[9]   An international survey of cancer pain characteristics and syndromes [J].
Caraceni, A ;
Portenoy, RK .
PAIN, 1999, 82 (03) :263-274
[10]   Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC [J].
Caraceni, Augusto ;
Hanks, Geoff Rey ;
Kaasa, Stein ;
Bennett, Michael I. ;
Brunelli, Cinzia ;
Cherny, Nathan ;
Dale, Ola ;
De Conno, Franco ;
Fallon, Marie ;
Hanna, Magdi ;
Haugen, Dagny Faksvag ;
Juhl, Gitte ;
King, Samuel ;
Klepstad, Pal ;
Laugsand, Eivor A. ;
Maltoni, Marco ;
Mercadante, Sebastiano ;
Nabal, Maria ;
Pigni, Alessandra ;
Radbruch, Lukas ;
Reid, Colette ;
Sjogren, Per ;
Stone, Patrick C. ;
Tassinari, Davide ;
Zeppetella, Giovambattista .
LANCET ONCOLOGY, 2012, 13 (02) :E58-E68